AI News>Press Release
- Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
- Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- Qifu Technology, Inc. Announces Pricing of Offering of US$600 Million Cash-par Settled Convertible Senior Notes
- Kolibri Global Energy Announces a 24% Increase in Production in 2024 With Record Annual Revenues and Adjusted EBITDA and Net Income of US$18.1 Million
- Cemex showcases significant operational and sustainability advancements in its 2024 Integrated Report
- StandardAero Announces Pricing of Its Upsized Secondary Offering of 36,000,000 Shares of Common Stock by Affiliates of The Carlyle Group Inc. and GIC Private Limited
- Biomea Fusion Announces Leadership Transition
- Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
- UL Solutions Opens Ningbo Retail and Consumer Products Laboratory to Help Manufacturers Advance Quality and Safety
- Government of Guyana, Mount Sinai Health System and Hess Corporation Announce Five-Year Extension of National Healthcare Initiative
- CSX Announces Tentative Labor Agreement with Boilermakers
- Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older
- United Rentals Selected as One of America's Best-Managed Companies
- Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
- Element Nominates Paolo Ferrari and Tracey McVicar for Election to the Board of Directors
- Navigator Gas Announces Availability of its Annual Report on Form 20-F for the Year Ended December 31, 2024
- HII's Ingalls Shipbuilding Launches Guided Missile Destroyer Future USS Jeremiah Denton (DDG 129)
- Genmab Announces Initiation of Share Buy-Back Program
- INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC
- Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
- Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
- Pioneer Closed-End Funds Announce Postponement of March 26, 2025 Special Meeting of Stockholders
- Weatherford Releases 2024 Digital Annual Update
- AirJoule Technologies Announces Fourth Quarter and Full Year 2024 Results and Groundbreaking Performance of AirJoule® System
- RAA and Duck Creek Technologies announce new SaaS core insurance delivery technology partnership
- Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
- Perion Announces Filing of Annual Report on Form 20-F for Fiscal Year 2024
- Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
- Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
- IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- Benson Hill Receives Court Approval of First-Day Motions to Support Ongoing Operations During Chapter 11 Process
- Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
- W&T Offshore Announces Management Promotion
- Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
- Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
- True North Mortgage Welcomes 25+ Former Rocket Mortgage Canada Employees, Expands Windsor and Quebec Presence
- Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
- Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
- Chimera Investment Corporation Sponsors Residential Mortgage Loan Securitizations
- AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
- Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
- Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting
- CLEAR and American Express Renew Partnership to Provide Premium Travel Experiences at Airports to Card Members
- Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
- Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
- Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
- iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
- Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting